Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy

Pediatr Infect Dis J. 2017 May;36(5):e123-e129. doi: 10.1097/INF.0000000000001478.

Abstract

Background: The effect of hepatitis C virus (HCV) coinfection on CD4 T cell recovery in treated HIV-infected children is poorly understood.

Objective: To compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children.

Method: We studied 355 HIV monoinfected and 46 HIV/HCV coinfected children receiving antiretroviral therapy (ART) during a median follow-up period of 4.2 years (interquartile range: 2.7-5.3 years). Our dataset came from the Ukraine pediatric HIV Cohort and the HIV/HCV coinfection study within the European Pregnancy and Paediatric HIV Cohort Collaboration. We fitted an asymptotic nonlinear mixed-effects model of CD4 T cell reconstitution to age-standardized CD4 counts in all 401 children and investigated factors predicting the speed and extent of recovery.

Results: We found no significant impact of HCV coinfection on either pre-ART or long-term age-adjusted CD4 counts (z scores). However, the rate of increase in CD4 z score was slower in HIV/HCV coinfected children when compared with their monoinfected counterparts (P < 0.001). Both monoinfected and coinfected children starting ART at younger ages had higher pre-ART (P < 0.001) and long-term (P < 0.001) CD4 z scores than those who started when they were older.

Conclusions: HIV/HCV coinfected children receiving ART had slower CD4 T cell recovery than HIV monoinfected children. HIV/HCV coinfection had no impact on pre-ART or long-term CD4 z scores. Early treatment of HIV/HCV coinfected children with ART should be encouraged.

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • Antiviral Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / virology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Coinfection
  • Drug Combinations
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / drug effects
  • HIV-1 / immunology
  • Hepacivirus / drug effects
  • Hepacivirus / immunology
  • Hepatitis C / drug therapy*
  • Hepatitis C / immunology
  • Hepatitis C / virology
  • Humans
  • Interferon-alpha / therapeutic use
  • Lamivudine / therapeutic use
  • Lopinavir / therapeutic use
  • Male
  • Models, Immunological*
  • Polyethylene Glycols / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Recovery of Function / immunology
  • Ribavirin / therapeutic use
  • Ritonavir / therapeutic use
  • Time-to-Treatment
  • Zidovudine / therapeutic use

Substances

  • Antiviral Agents
  • Drug Combinations
  • Interferon-alpha
  • Recombinant Proteins
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Lamivudine
  • Polyethylene Glycols
  • Ribavirin
  • Zidovudine
  • Ritonavir
  • peginterferon alfa-2a